Physician profile
Jason Daniel Lee
NPI 1407111339
$3,005.55
in general payments reported to CMS, 2019-2025
34 companies · $511 in 2025
The $511 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $885 · 2020: $260 · 2022: $181 · 2023: $707 · 2024: $461 · 2025: $511.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,680.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,679.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $502.28 | 2019-2025 | Wegovy |
| Abbvie INC. | $400.73 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $381.71 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Pfizer INC. | $173.65 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $169.23 | 2019-2025 | Jardiance |
| Allergan, INC. | $145.77 | 2020 | |
| Lilly USA, LLC | $125.46 | 2020-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $111.82 | 2019-2024 | Otezla, Repatha, Prolia |
| Exact Sciences Corporation | $102.30 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Otsuka America Pharmaceutical, INC. | $77.74 | 2023-2025 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $77.19 | 2024-2025 | |
| Abbott Laboratories | $76.31 | 2023-2025 | Freestyle Libre 3 |
| Gilead Sciences, INC. | $62.49 | 2023-2024 | |
| Tris Pharma INC | $57.99 | 2019-2022 | |
| Sanofi Pasteur INC. | $54.49 | 2019-2023 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $49.33 | 2019-2024 | Xifaxan |
| Novartis Pharmaceuticals Corporation | $45.08 | 2022 | |
| Corium, LLC | $39.97 | 2023-2024 | Azstarys |
| Glaxosmithkline, LLC. | $35.88 | 2023-2024 | Trelegy Ellipta |
| Merck Sharp & Dohme LLC | $32.36 | 2022-2025 | Vaxneuvance, Proquad, Enflonsia |
| Cranial Technologies, INC | $31.61 | 2023-2024 | Doc Band |
| Ironshore Pharmaceuticals INC. | $24.34 | 2023 | Jornay Pm |
| Amarin Pharma, INC. | $24.18 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $23.96 | 2019 | |
| Eisai INC. | $23.44 | 2019 | |
| Hologic Sales and Service, LLC | $20.52 | 2023 | Coolseal Generator |
| Tempus Ai, INC | $20.09 | 2024 | |
| Neos Therapeutics, LP | $19.62 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.70 | 2023 | Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $17.55 | 2024 | Caplyta |
| Dexcom, INC. | $17.42 | 2024 | Dexcom G6 Transmitter |
| Adlon Therapeutics L.P. | $16.14 | 2020 | |
| Halozyme INC | $14.02 | 2023 | |
| Dynavax Technologies Corporation | $13.18 | 2025 | Heplisav-B |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.